Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.06. | Oncoinvent ASA: Oncoinvent: Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | 1 | Oslo Børs | ||
18.06. | Oncoinvent AS: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin in Patients with Colorectal Peritoneal Metastases | 212 | PR Newswire | Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer
OSLO... ► Artikel lesen | |
18.06. | Oncoinvent ASA: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | 2 | Oslo Børs | ||
14.05. | Oncoinvent ASA: Minutes from the annual general meeting 2025 | - | Oslo Børs | ||
30.04. | Oncoinvent Q1 2025 slides: promising cancer therapy data, solid cash position | 1 | Investing.com | ||
ONCOINVENT Aktie jetzt für 0€ handeln | |||||
30.04. | Oncoinvent ASA: Notice of Annual General Meeting | - | Oslo Børs | ||
28.04. | Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update | 185 | PR Newswire | OSLO, Norway, April 28, 2025 /PRNewswire/ -- In connection with the release of the first quarter 2025 company update, Oncoinvent invites for a Live streamed of quarterly presentation in English... ► Artikel lesen | |
28.04. | Oncoinvent ASA: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression | 3 | Oslo Børs | ||
28.04. | Oncoinvent AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression | 235 | PR Newswire | OSLO, Norway, April 28, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the 18-month... ► Artikel lesen | |
28.04. | ONCOINVENT AS: Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression | 3 | Cision News | ||
28.04. | Oncoinvent ASA: Financial calendar | 1 | Oslo Børs | ||
25.03. | Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients | 1 | Oslo Børs | ||
05.03. | Oncoinvent ASA: Mandatory notification of trade | - | Oslo Børs | ||
27.02. | Oncoinvent ASA: Fourth Quarter 2024 Update and Results | 1 | Cision News | ||
27.02. | Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients | 1 | Cision News | ||
26.02. | Oncoinvent ASA: Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference | 253 | Business Wire | Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference... ► Artikel lesen | |
20.02. | Oncoinvent ASA: Invitation to Result Presentation Q4 2024 | 408 | PR Newswire | OSLO, Norway, Feb. 20, 2025 /PRNewswire/ -- In connection with the release of the results for the full year and fourth quarter 2024, Oncoinvent invites to the following events:
Thursday... ► Artikel lesen | |
19.02. | Oncoinvent ASA to present at various conferences | - | Oslo Børs | ||
18.02. | Oncoinvent ASA: Registration of new share capital | - | Oslo Børs | ||
06.02. | Oncoinvent ASA: Last day of the subscription period in the subsequent offering | 1 | Oslo Børs |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 40,330 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
QIAGEN | 41,085 | -0,35 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
ADMA BIOLOGICS | 18,380 | 0,00 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,020 | 0,00 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
KEROS THERAPEUTICS | 13,510 | 0,00 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
EVOTEC | 7,190 | -0,08 % | Evotec Aktie mit Verkaufssignal: Konter oder Sturz auf 5 Euro? | Die Evotec Aktie hat am Donnerstag ein charttechnisches Verkaufssignal ausgelöst. Mit einem XETRA-Schlusskurs von 6,568 Euro fiel der Kurs um mehr als vier Prozent und unterschritt dabei mehrere relevante... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
IMMUNOME | 8,790 | 0,00 % | Immunome Inc. - 8-K, Current Report |